Paper Details

  1. Home
  2. Paper Details

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.

Author: BlancoJose L, GatellJose M, González-CordonAna, LagunoMontserrat, LoncaMontserrat, MallolasJosep, MartínezEsteban, Martínez-RebollarMaria, MonteiroPolyana, PerezIñaki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dual therapy with etravirine plus raltegravir was well tolerated and maintained durable viral suppression in selected virologically suppressed patients for whom both protease inhibitor (PI) and nucleoside reverse transcriptase inhibitor (NRTI) therapy was challenging.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Clinical use of protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) may be hampered by toxicity, interactions or resistance issues. Simple and effective antiretroviral regimens avoiding both drug classes may be needed for selected patients. METHODS: This wa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dkt406

データ提供：米国国立医学図書館（NLM）

Dual Therapy for Virologically Suppressed HIV-Infected Patients

This research explores the use of dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients who have experienced difficulties with traditional antiretroviral regimens. The study involved 25 patients who were switched to etravirine plus raltegravir after experiencing problems with tolerability, safety concerns due to comorbidities, or drug interactions. The authors found that dual therapy with etravirine plus raltegravir was well tolerated and maintained durable viral suppression in these patients. This research suggests that dual therapy may be a viable alternative for certain HIV-infected patients who have struggled with traditional antiretroviral regimens.

Dual Therapy - A New Path for HIV Treatment

This study provides evidence that dual therapy with etravirine plus raltegravir can effectively maintain viral suppression in selected HIV-infected patients. The findings suggest that this therapy could be a valuable alternative for patients who have experienced difficulties with traditional antiretroviral regimens. Further research is needed to confirm these findings and to identify the optimal patient population for this type of treatment.

Living with HIV: The Importance of Personalized Treatment

This research highlights the importance of personalized treatment for HIV-infected patients. There is no one-size-fits-all approach to HIV management. It is essential to work closely with your doctor to develop an effective treatment plan that meets your individual needs and goals.

Dr. Camel's Conclusion

This research is like a camel caravan navigating the vast and ever-changing landscape of HIV treatment. By exploring new treatment options and developing more effective and tolerable therapies, we can help patients living with HIV achieve a better quality of life. This research is a reminder that with a bit of camel-powered determination and ingenuity, we can overcome even the most challenging medical obstacles.

Date :
  1. Date Completed 2015-07-15
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

24128667

DOI: Digital Object Identifier

10.1093/jac/dkt406

Related Literature

Article Analysis
・Side Effects of etravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.